Three years of experience: the Italian registry and safety data update
Gianluigi Mancardi(Istituti Clinici Scientifici Maugeri), Leandro Provinciali(Ospedali Riuniti di Ancona), Maria Giovanna Marrosu(University of Cagliari), Giovanni Savettieri(University of Palermo), Alice Laroni(Azienda Ospedaliera di Padova), Rosamaria Iommelli(Italian Medicines Agency), Nicola Vanacore(Ministero della Salute), Gıancarlo Comı(Casa di Cura Columbus), Maria Pia Amato(University of Florence), Carlo Tomino, Filippo Drago(University of Catania), Nicola Montanaro(University of Bologna), Carlo Piccinni(University of Bologna), Carlo Pozzilli(Sapienza University of Rome), Anna Covezzoli(Cineca), Roberto D’Alessandro(Inserm), Paolo Rossi(Associazione Italiana Sclerosi Multipla), P. Popoli(Italian Medicines Agency), G. Tedeschi(Italian Medicines Agency), Luigi M.E. Grimaldi, C. Milanese(Fondazione IRCCS Istituto Neurologico Carlo Besta), M. R. Tola(Vita-Salute San Raffaele University), Antonio Bertolotto(Neuroscience Institute), M. De Rosa(Cineca), Laura Periotto(Italian Medicines Agency)
Cited by 32
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Multiple Sclerosis Severity Score
|Neurology|2005|959
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
|Neuron|2018|724